Table 1.
Summary of active clinical trials investigating Parkinson’s disease in relation to oxidative stress. The studies have been retrieved from clinicaltrials.gov with search keywords “Condition or disease = Parkinson disease” and “Other terms = oxidative stress” and selecting the items with the status “Recruiting” and “Active, not recruiting”.
| ClinicalTrials.gov Identifier | Official Title | Intervention/ Treatment |
Phase | Estimated Completion Date | Ref. |
|---|---|---|---|---|---|
| NCT04459052 | Phase II: Physiological Effects of Nutritional Support in Patients With Parkinson’s Disease | Dietary Supplement: N-acetylcysteine Drug: [F-18] Fluorodopa Positron Emission Tomography |
Phase 2 | 1 May 2023 | [25] |
| NCT02445651 | Physiological Effects of Nutritional Support in Patients With Parkinson’s Disease | Dietary Supplement: Intravenous and Oral N-acetylcysteine | Not applicable | 6 December 2021 | [26] |
| NCT05214287 | An N-of-1 Double-blind Randomized Phase 1 Trial of the Safety and Feasibility of (Intermittent) Hypoxia Therapy in Parkinson’s Disease | Drug: Hypoxic Gas Mixture | Phase 1 Phase 2 |
February 2023 | [27] |
| NCT05110547 | Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson’s Disease From Related Conditions | Biological: Blood Collection | Not applicable | April 2023 | [28] |
| NCT02524405 | The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration | Other: Pittsburgh Compound B [11C]-PIB | Not applicable | December 2023 | [29] |
| NCT04491383 | Tocotrienols in Parkinson’s Disease (PD): A Pilot, Randomised, Placebo-controlled Trial | Drug: Tocovid Suprabio (HOV-12020) Other: Placebo |
Phase 2 | December 2024 | [30] |